Physician profile
Niranjan Shah
NPI 1184662470
$2,064.96
in general payments reported to CMS, 2019-2025
15 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $22.66 · 2021: $85.68 · 2022: $357 · 2023: $200 · 2024: $291 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $570.95 | 2021-2025 | Verquvo |
| Pfizer INC. | $281.97 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $220.20 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $202.20 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $135.88 | 2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $131.25 | 2025 | Airsupra, Breztri |
| Biotronik INC. | $118.61 | 2025 | Biomonitor, Amvia Edge |
| Novo Nordisk INC | $117.81 | 2025 | Wegovy |
| Abbott Laboratories | $105.76 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $43.22 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $39.60 | 2021-2023 | Definity |
| Glaxosmithkline, LLC. | $34.25 | 2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.90 | 2022-2023 | Jardiance |
| Inspire Medical Systems, INC. | $21.92 | 2024 | Inspire |
| Amarin Pharma, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranjan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.